“Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis”, Swiss Med Wkly, vol. 140, no. 2728, p. w13073, Jul. 2010, doi: 10.4414/smw.2010.13073.